GPCR · Structure Therapeutics Inc. American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow GPCR by emailGet an email when GPCR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GPCR, unsubscribe in one click. Privacy
📣 What GPCR Says Is Next
1H 2027 · “ALENIGLIPRON On track to complete enrollment by 1H 2027 and topline data in 2H 2028 30 Advancing Aleniglipron as a Potential Best - in - Class Oral GLP - 1 Phase 3 Design”
Company press release, Sep 8, 2026 · SEC filing
fourth quarter of 2026 · “Upcoming Milestones in Q4 2026 Additional clinical data expected in the fourth quarter of 2026 could further define aleniglipron’s differentiated clinical profile in terms of the quality of weight loss, treatment of patients with T2DM and the transition from approved injectable incretin medicines.”
Company press release, Sep 8, 2026 · SEC filing
second half of 2028 · “We expect topline data in the second half of 2028.”
Company press release, Sep 8, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full GPCR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GPCR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.